Show simple item record

dc.contributor.authorMiao, Jien_US
dc.contributor.authorLing, Alisha V.en_US
dc.contributor.authorManthena, Praveen V.en_US
dc.contributor.authorGearing, Mary E.en_US
dc.contributor.authorGraham, Mark J.en_US
dc.contributor.authorCrooke, Rosanne M.en_US
dc.contributor.authorCroce, Kevin J.en_US
dc.contributor.authorEsquejo, Ryan M.en_US
dc.contributor.authorClish, Clary B.en_US
dc.contributor.authorTorrecilla, Estheren_US
dc.contributor.authorVázquez, Gumersindo Fernándezen_US
dc.contributor.authorRubio, Miguel A.en_US
dc.contributor.authorCabrerizo, Lucioen_US
dc.contributor.authorBarabash, Anaen_US
dc.contributor.authorPernaute, Andrés Sánchezen_US
dc.contributor.authorTorres, Antonio J.en_US
dc.contributor.authorVicent, Daviden_US
dc.contributor.authorBiddinger, Sudha B.en_US
dc.date.accessioned2015-05-04T15:25:38Z
dc.date.issued2015en_US
dc.identifier.citationMiao, J., A. V. Ling, P. V. Manthena, M. E. Gearing, M. J. Graham, R. M. Crooke, K. J. Croce, et al. 2015. “Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.” Nature Communications 6 (1): 6498. doi:10.1038/ncomms7498. http://dx.doi.org/10.1038/ncomms7498.en
dc.identifier.issn2041-1723en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:15034764
dc.description.abstractDespite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 (Fmo3) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro, increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.en
dc.language.isoen_USen
dc.publisherNature Pub. Groupen
dc.relation.isversionofdoi:10.1038/ncomms7498en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391288/pdf/en
dash.licenseLAAen_US
dc.titleFlavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosisen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalNature Communicationsen
dash.depositing.authorMiao, Jien_US
dc.date.available2015-05-04T15:25:38Z
dc.identifier.doi10.1038/ncomms7498*
dash.authorsorderedfalse
dash.contributor.affiliatedGearing, Mary E.
dash.contributor.affiliatedMiao, Ji
dash.contributor.affiliatedCroce, Kevin
dash.contributor.affiliatedLing, Alisha
dash.contributor.affiliatedBiddinger, Sudha


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record